Retina Society 2024: Key Findings from FARETINA and FARWIDE Studies
Exploring the FARETINA and FARWIDE Studies at Retina Society 2024
Ophthalmology Times reported on the latest findings shared by Dr. Durga Borkar at the Retina Society meeting. She presented compelling data regarding the 12-month outcomes of the FARETINA and FARWIDE studies aimed at evaluating faricimab in real-world settings.
Key Outcomes of FARETINA and FARWIDE Studies
- Both studies revealed substantial gains in vision for treatment-naive patients.
- FARETINA patients experienced a remarkable average increase of 3 letters of vision after 6 injections.
- FARWIDE patients showcased an even more impressive 8 letters of visual acuity.
The findings suggest that incorporating faricimab early in treatment may yield better outcomes and reduce treatment burden.
Implications for Retina Specialists
Dr. Borkar emphasized the importance for retina specialists to consider faricimab as a viable option for diabetic macular edema (DME) treatment. Utilizing data from these studies, clinicians can refine their approaches and significantly enhance patient care.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.